EA202192164A1 - Контрастный агент для кт для детекции кахексии - Google Patents

Контрастный агент для кт для детекции кахексии

Info

Publication number
EA202192164A1
EA202192164A1 EA202192164A EA202192164A EA202192164A1 EA 202192164 A1 EA202192164 A1 EA 202192164A1 EA 202192164 A EA202192164 A EA 202192164A EA 202192164 A EA202192164 A EA 202192164A EA 202192164 A1 EA202192164 A1 EA 202192164A1
Authority
EA
Eurasian Patent Office
Prior art keywords
contrast agent
cachexia
detection
iodinated
bat
Prior art date
Application number
EA202192164A
Other languages
English (en)
Inventor
Андрей Бабич
Натали Странски-Хайлькрон
Original Assignee
Юниверсите Де Женев
Адипосс Сарл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсите Де Женев, Адипосс Сарл filed Critical Юниверсите Де Женев
Publication of EA202192164A1 publication Critical patent/EA202192164A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0495—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound intended for oral administration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways
    • G01N2800/7066—Metabolic pathways
    • G01N2800/7085—Lipogenesis or lipolysis, e.g. fatty acid metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Изобретение относится к иодированному контрастному агенту для КТ для неинвазивной диагностики кахексии. Эта возможность обеспечивается превосходным разрешением КТ в комбинации с контрастным агентом для КТ, специфическим для коричневой и/или бежевой жировой ткани (BAT).
EA202192164A 2019-02-13 2020-02-13 Контрастный агент для кт для детекции кахексии EA202192164A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157026 2019-02-13
PCT/EP2020/053768 WO2020165349A1 (en) 2019-02-13 2020-02-13 Ct contrast agent for detection of cachexia

Publications (1)

Publication Number Publication Date
EA202192164A1 true EA202192164A1 (ru) 2021-11-19

Family

ID=65440791

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192164A EA202192164A1 (ru) 2019-02-13 2020-02-13 Контрастный агент для кт для детекции кахексии

Country Status (12)

Country Link
US (1) US20220160900A1 (ru)
EP (1) EP3923996A1 (ru)
JP (1) JP2022521371A (ru)
KR (1) KR20210130748A (ru)
CN (2) CN118178688A (ru)
AU (1) AU2020223505A1 (ru)
BR (1) BR112021014860A8 (ru)
CA (1) CA3128858A1 (ru)
EA (1) EA202192164A1 (ru)
IL (1) IL285353B2 (ru)
SG (1) SG11202108733XA (ru)
WO (1) WO2020165349A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4192521A1 (en) 2020-08-06 2023-06-14 Adiposs SA Pet-ct imaging methods, contrast agents and pharmaceutical compositions for use in said imaging methods
WO2023073195A1 (en) 2021-10-28 2023-05-04 Adiposs SA Emulsions, compositions for emulsions, methods for making the same and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73958A (en) * 1983-12-29 1991-03-10 Rubin Daniel Lee Contrast agents containing iodinated aliphatic carboxylic acids for gastrointestinal tract radiography
CN111194225B (zh) * 2017-08-07 2023-01-13 日内瓦大学 用于ct成像的碘化脂肪酸的纳米乳剂

Also Published As

Publication number Publication date
CA3128858A1 (en) 2020-08-20
AU2020223505A1 (en) 2021-08-12
WO2020165349A1 (en) 2020-08-20
BR112021014860A2 (pt) 2021-10-05
CN113784734A (zh) 2021-12-10
BR112021014860A8 (pt) 2022-06-28
EP3923996A1 (en) 2021-12-22
KR20210130748A (ko) 2021-11-01
IL285353B2 (en) 2023-06-01
IL285353A (en) 2021-09-30
SG11202108733XA (en) 2021-09-29
CN118178688A (zh) 2024-06-14
JP2022521371A (ja) 2022-04-07
US20220160900A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
EA202192164A1 (ru) Контрастный агент для кт для детекции кахексии
CO2021015520A2 (es) Combinación de marcador de mirna y kit para el diagnóstico del cáncer gástrico
WO2016133848A3 (en) Therapeutic angiogenesis for treating erectile conditions
EA202090139A1 (ru) Контрастный агент для компьютерной томографии
ATE471694T1 (de) Implantierbares medizinprodukt zur beurteilung eines grads von lungenödem eines patienten
TWD196636S (zh) 心電圖裝置
JP1737942S (ja) 医療用穿刺針デバイス
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
WO2015173841A3 (en) Echo-scintigraphic probe for medical applications and relevant diagnostic method
EP4336183A3 (en) Improved methods and devices for accurate diagnosis of infections
NZ760756A (en) Biomarkers for the diagnosis and treatment of fibrotic lung disease
EA202190755A1 (ru) Агенты для терапии и диагностики рака
MX2022004017A (es) Deteccion de analitos por medio de interruptores de proteinas.
TW201612520A (en) Tumor examination composition and test paper for tumor examination
EA201001297A1 (ru) Способ диагностики меланомы человека на основании определения уровня экспрессии гена phf10, диагностический набор
de Los Ríos Questionnaires for the diagnosis of gastroesophageal reflux disease: are they really useful?
PL430530A1 (pl) Sposób diagnostyki zaburzeń rytmu serca z wykorzystaniem telemetrycznego systemu do ciągłego rejestrowania pracy serca u pacjentów kierowanych do leczenia zabiegowego arytmii
UA124885U (uk) Спосіб лікування хворих із шлунково-кишковою кровотечею
Said et al. A Toddler with Abdominal Pain and Emesis
RU2013131933A (ru) Способ диагностики ректоанального ингибиторного рефлекса
Bianchi et al. Comparison of the traditional human Auscultatory method versus Doppler and Oscillometric techniques for indirect blood pressure measurement: a pilot study in anaesthetised dogs
조현규 et al. S-14: Hepatic resection versus radiofrequency ablation for single HCC up to 5 cm in diameter
Mazurek et al. B108 BEYOND WHO GROUP I PULMONARY HYPERTENSION: Non-Invasive Assessment Of Right Ventricular-Pulmonary Artery Interaction Predicts An Elevated Diastolic-To-Wedge Gradient In Patients With Left Heart Disease-Associated Pulmonary Hypertension
Ryu et al. Lymphedema Induced by Recurrent Myxedema
Saffioti et al. Spleen stiffness measurement with ElastPQ point shear wave elastography has an excellent performance in predicting the presence of clinically significant portal hypertension in primary biliary cholangitis